Oct. 24 (Bloomberg) -- H. Lundbeck A/S, maker of the antidepressant Lexapro, won approval for a drug to treat seizures associated with a rare and severe form of childhood epilepsy.
The Food and Drug Administration cleared the adjunctive therapy called Onfi, the agency said today in a statement. The medicine, chemically known as clobazam, may reach peak sales of $175 million, Peter Welford, an analyst at Jefferies International in London, wrote in a note to clients Sept. 28.
To contact the reporter on this story: Anna Edney in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Adriel Bettelheim at email@example.com